Efficacy of fusafungine in acute rhinopharyngitis: A pooled analysis

Rhinology

Volumn 42, Issue 4, 2004, Pages 207-212

  Lund, Valerie J ^a   Grouin, J M ^b   Eccles, R ^c   Bouter, C ^d   Chabolle, F ^e  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITÉ DE ROUEN   (France)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d Novella   (Netherlands)

^e FOCH HOSPITAL   (France)

Author keywords

Fusafungine; Nasal symptom score; Rhinopharyngitis

Indexed keywords

FUSAFUNGINE; PLACEBO;

ACUTE DISEASE; ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIOSTASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DOSE TIME EFFECT RELATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PARALLEL DESIGN; RESPIRATORY TRACT DISEASE; RHINOPHARYNGITIS; RISK ASSESSMENT; SCORING SYSTEM; SKIN MANIFESTATION; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ACUTE DISEASE; ADMINISTRATION, TOPICAL; ADULT; AEROSOLS; ANTI-BACTERIAL AGENTS; DOUBLE-BLIND METHOD; FEMALE; FUSARIUM; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGITIS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 10044281100     PISSN: 03000729     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Abruzzi WA, Cohen BM (1968) Comparative study of an aerosol of pressurized Locabiotal and a placebo in the treatment of infections of the upper respiratory passages. Med Int 3: 819-835 (in French).
2. Alexander DJ (1995a) Safety of propellants. J Aerosol Med 8 Suppl 1: S29-34.
3. Alexander DJ, Libretto SE (1995b) An overview of the toxicology of HFA 134a (1,1,1,2-tetrafluoroethane). Hum Exp Toxicol 14: 715-720.
4. Cuenant G (1988) Value of Locabiotal aerosol in rhinosinusitis. Rhinology (suppl 5): 69-74.
5. Eccles R (1994) Menthol and related cooling compounds. J Pharm Pharmacol 46: 618-630.
6. Fagnani F, German-Fattal M (2003) Antibiotic prescribing patterns of French GPs for upper respiratory tract infections. Am J Respir Med 2: 1-8.
7. Feutren G (1980) Locabiotal® aerosol spray: a multicenter study in 2002 patients. Vie médicale 61: 1-6 (in French).
8. German-Fattal M (1989) Bactericidal activity of fusafungine towards nosocomial methicillin-resistant staphylococcal strains and towards Haemophilus influenzae. Maladies et médicaments 5: 97-104 (a) (in French).
9. German-Fattal M (1994) Current aspects of the antimicrobial spectrum of fusafungine. Ann Otolaryngol Chir Cervicofac 111: 43-46 (a) (in French).
10. German-Fattal M (2001) Fusafungine, an antimicrobial with anti-inflammatory properties in respiratory tract infections. Review and recent advances in cellular and molecular activity. Clin Drug Invest 21: 653-670.
11. Gonzales R, Bartlett JG, Besser RE, Hickner JM, Hoffman JR, Sande MA (2001) Principles of appropriate antibiotics use for treatment of non specific upper respiratory tract infections in adults. Background. Ann Intern Med 134: 490-494.
12. Gosset P, Wallaert B, Crambes O, Girard V, Malbezin M, Tonnel AB (1996) Fusafungine inhibits the production of anion superoxide and cytokines by human alveolar macrophages. Eur Respir J Suppl 9: P2860.
13. Gwaltney JM Jr, Druce HM (1997) Efficacy of brompheniramine maleate for the treatment of rhinovirus colds. Clinical Infectious Diseases 25: 1188-1194.
14. Hamann KF (1994). Treatment of isolated acute laryngitis with fusafungine, HNO 42: 113-118 (in German).
15. Heikkinen T, Järvinen A (2003). The common cold. Lancet 361: 51-59.
16. Jackson GG, Dowling HF, Spiesman IG, Boand AV (1958) Transmission of the common cold to volunteers under controlled conditions. The common cold as a clinical entity. Arch Intern Med 101: 267-278.
17. Jousserandot P, Gremain J, Du-Boistesselin R (1981) Use of histological methods for the demonstration of the anti-inflammatory activity of fusafungine. Sem Hop Paris 57: 143-150 (in French).
18. Kaiser L, Lew D, Hirschel B, Auckenthaler R, Morabia A, Heald A (1996) Effects of antibiotic treatment in the subset of common-cold patients who have bacteria in nasopharyngeal secretions. Lancet 347: 1507-1510.
19. Laccourreye O, Cauchois R, Landais P, German-Fattal M (2003) The impact of fusagungine on the prescription of antibiotics in the treatment of rhinopharyngitis. Presse Med 32: 615-619.
20. Mainous AG 3rd, Hueston WJ (1996) Antibiotics for the common cold. Lancet 348: 754.
21. Otori N, Paydas G, Stierna P, Westrin KM (1998) The anti-inflammatory effect of fusafungine during experimentally induced rhinosinusitis in the rabbit. Eur Arch Otorhinolaryngol 255: 195-201.
22. Pandraud L (2002) Therapeutic efficacy and clinical acceptability of fusafungine in follicular pharyngitis. Current Medical Research and Opinions 18: 381-388.
23. Prasad AS, Fitzgerald JT, Bao B, Beck FWJ, Chandraseka PH (2000) Duration of symptoms and plasma cytokine levels in patients with the common cold treated with zinc acetate. Ann Intern Med 133: 245-252.
24. Reinert P (1989) Value of a rapid test for the detection of streptococcal infections: illustration by a study of Locabiotal aerosol in Tonsillitis. Drugs Dis 5: 113-123.
25. Samolinski B, Zawisza E, Arcimowicz M, Czapska M, Zmigrodzki B (1997) Influence of fusafungine upon viral and bacterial infections. Med Sci Monit 3: 736-743.
26. Turner RB (1997) Epidemiology, pathogenesis and treatment of the common cold. Ann Allergy Asthma Immunol 78: 531-540.
27. Turner RB (2001) The treatment of rhinovirus infections: progress and potential. Antiviral Research 49: 1-14.
28. Van Kempen M, Bachert C, Van Cauwenberge P (1999) An update on the pathophysiology of rhinovirus upper respiratory tract infections. Rhinology 37: 97-103.
29. Whitehead A (1991) A general parametric approach to the meta-analysis of randomised clinical trials. Statistics in Medicine 10: 1665-1991.